How PBI/Gordon Companies leveraged our Sirolimus API Market report
VM Intelligence · Sample preview · Healthcare and Pharmaceuticals · Forecast 2027–2033
Tumor Cell Sorter Market
- By Product Type: Benchtop Cell Sorters, Floor-standing Cell Sorters, Portable Cell Sorters
- By Technology: Fluorescence-Activated Cell Sorting (FACS), Magnetic-Activated Cell Sorting (MACS), Microfluidic Cell Sorting, Impedance-Based Cell Sorting
- By Application: Cancer Research, Immunology, Stem Cell Research, Drug Discovery and Development, Clinical Diagnostics
- By End User: Research Laboratories, Pharmaceutical and Biotechnology Companies, Hospitals and Diagnostic Centers, Academic and Government Institutes
- By Sorting Mode: Single Cell Sorting, Bulk Cell Sorting, High-Speed Sorting
Key Highlights
A snapshot of what the full report proves- 01 Market size - $X,XXX.XM global market in 2025 - the verified base-year revenue. Executive Summary →
- 02 Forecast - Full 2033 market projection modelled inside - unlock the forecast value to see where the market lands. Market Outlook →
- 03 Growth - Year-by-year CAGR across 2027–2033 - unlock the growth rate and the full model. Market Outlook →
- 04 Leading segment - Benchtop Cell Sorters leads By Product Type at XX% share. Market, by Service Type →
- 05 Global coverage - Sized across 5 regions and 20 countries, each broken out by segment. Market, by Geography →
- 06 Competitive landscape - 13 companies profiled with SWOT, benchmarking and market-share analysis. Company Profiles →
Inside the Report
12 chapters · 287 pages- 01 Introduction Definition, segmentation & scope p.12 →
- 02 Research Methodology How the numbers were built p.20 →
- 03 Executive Summary The market in one chapter p.34 →
- 04 Market Outlook Drivers, restraints, trends p.66 →
- 11 Competitive Landscape 5 sections p.176 →
- 12 Company Profiles 13 players: SWOT & benchmarking p.184 →
Full report · locked preview
Everything inside the Tumor Cell Sorter Market report
A complete, evidence-based study - 12 chapters and 120 sections covering market size, segmentation across 5 axes, regional analysis and 13 company profiles, forecast to 2033.
Segmentation covered
Product Type 3
Technology 4
Application 5
End User 4
Sorting Mode 3
Companies profiled
BD Biosciences
Beckman Coulter Life Sciences
Sony Biotechnology
Miltenyi Biotec
Bio-Rad Laboratories
Sysmex Corporation
Thermo Fisher Scientific
Agilent Technologies
ACEA Biosciences (a Sartorius company)
Union Biometrica
Partec GmbH
Cytek Biosciences
+1 more
Verified · Analyst-reviewed · No payment to preview
Trusted & certified by
★★★★★ Excellent
★★★★★ Excellent
13 players profiled - tiered by revenue contribution, footprint and R&D capability.
ACE Matrix · p.153 →BD Biosciences
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.155 →Beckman Coulter Life Sciences
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.160 →Sony Biotechnology
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.166 →Miltenyi Biotec
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.173 →Bio-Rad Laboratories
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.178 →Sysmex Corporation
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.184 →Thermo Fisher Scientific
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.191 →Agilent Technologies
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.196 →ACEA Biosciences (a Sartorius company)
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.202 →Union Biometrica
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.209 →Partec GmbH
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.214 →Cytek Biosciences
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.220 →NanoCellect Biomedical
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.227 →Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Global · 2025–2033
$6,583M by 2033 · 6.0% CAGR
Market estimates & forecast (USD Million)
Fig. 15 · p.34 →Segment mix, 2033 (% share)
Fig. 16 · p.35 →- Benchtop Cell Sorters69.6
- Floor-standing Cell Sorters13.2
- Portable Cell Sorters17.1
Regions, 2025 → 2033 (USD Mn)
§6.1 · p.75 →North America$1,366M → $2,174M · 6.0%
Europe$952.2M → $1,539M · 6.2%
Asia Pacific$869.4M → $1,331M · 5.5%
Latin America$538.2M → $823.9M · 5.5%
Middle East and Africa$414.0M → $702.7M · 6.8%
Top countries, 2033 (USD Mn)
§6.2 · p.78 →Year-over-year growth (%)
§3.12 · p.44 →5.932026
5.932027
5.952028
5.952029
5.982030
5.992031
6.002032
6.002033
CAGR by region (%)
Fig. 22 · p.71 →Market share by company, 2033 (%)
Fig. 41 · p.152 →- BD Biosciences15.5
- Beckman Coulter Life Sciences24.8
- Sony Biotechnology7.7
- Miltenyi Biotec5.8
- Bio-Rad Laboratories7.9
- Sysmex Corporation10.4
- Others27.9
Segment contribution to growth (%)
Fig. 18 · p.39 →Product Type13.8%
Technology24.6%
Application17.7%
End User25.1%
Sorting Mode18.9%
Competitive positioning (ACE matrix)
Fig. 40 · p.153 →Adoption & penetration (% of addressable)
Fig. 12 · p.31 →Revenue by application (USD Mn)
§5.3 · p.62 →Demand by end-use (USD Mn)
§5.4 · p.66 →Average selling price trend (index, 2025=100)
Fig. 27 · p.58 →Top companies by revenue, 2033 (USD Mn)
Fig. 42 · p.155 →Revenue by region, 2033 (%)
Fig. 20 · p.70 →- North America33.1
- Europe23.4
- Asia Pacific20.3
- Latin America12.5
- Middle East and Africa10.7
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
8 players benchmarked across 6 dimensions — scored 0–100 from share, portfolio, reach, innovation, financials and installed base. Methodology · §8.1 · p.160 →
Competitive scorecard (score 0–100)
Table 31 · p.161 →| Company | Market share | Product portfolio | Geographic reach | Innovation & R&D | Financial strength | Customer base | Composite |
|---|---|---|---|---|---|---|---|
| BD Biosciences | 84 | 91 | 74 | 81 | 83 | 88 | 84 |
| Beckman Coulter Life Sciences | 86 | 92 | 71 | 74 | 68 | 75 | 78 |
| Sony Biotechnology | 69 | 77 | 84 | 87 | 74 | 81 | 79 |
| Miltenyi Biotec | 82 | 68 | 76 | 78 | 61 | 67 | 72 |
| Bio-Rad Laboratories | 62 | 55 | 62 | 63 | 70 | 76 | 65 |
| Sysmex Corporation | 47 | 53 | 56 | 65 | 46 | 52 | 53 |
| Thermo Fisher Scientific | 60 | 40 | 43 | 56 | 63 | 45 | 51 |
| Agilent Technologies | 51 | 57 | 36 | 43 | 50 | 54 | 49 |
Vendor positioning (presence × innovation)
Fig. 43 · p.163 →Strengths profile (top 3 players)
Fig. 44 · p.165 →- BD Biosciences
- Beckman Coulter Life Sciences
- Sony Biotechnology
Capability coverage
§8.3 · p.168 →| Company | Global delivery | R&D depth | Digital platform | Sustainability | After-sales | Custom solutions |
|---|---|---|---|---|---|---|
| BD Biosciences | ✓ | ✓ | ✓ | ◐ | ◐ | ✓ |
| Beckman Coulter Life Sciences | ◐ | ◐ | ◐ | ◐ | − | ◐ |
| Sony Biotechnology | − | ◐ | ◐ | ◐ | ◐ | ✓ |
| Miltenyi Biotec | ✓ | − | ◐ | ◐ | ◐ | ◐ |
| Bio-Rad Laboratories | ◐ | ◐ | − | − | ◐ | ◐ |
| Sysmex Corporation | − | − | ◐ | ✓ | − | ◐ |
| Thermo Fisher Scientific | − | − | − | ◐ | − | − |
| Agilent Technologies | − | ◐ | − | − | ◐ | − |
✓ Full ◐ Partial − Limited
Overall competitive index (composite, ranked)
Fig. 45 · p.170 →1BD Biosciences84
2Sony Biotechnology79
3Beckman Coulter Life Sciences78
4Miltenyi Biotec72
5Bio-Rad Laboratories65
6Sysmex Corporation53
7Thermo Fisher Scientific51
8Agilent Technologies49
Competitive tiers
§8.4 · p.172 →Leader3
Set the pace on share, breadth and innovation.
BD BiosciencesBeckman Coulter Life SciencesSony Biotechnology
Challenger1
Strong scale, closing on the leaders.
Miltenyi Biotec
Contender1
Focused players with pockets of strength.
Bio-Rad Laboratories
Niche3
Specialists in a single segment or region.
Sysmex CorporationThermo Fisher ScientificAgilent Technologies
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Go-to-market strategy
Land Product Type in North America, then scale across Tumor Cell Sorter Market — a $253M beachhead inside a $3.95B market.
Beachhead (SOM)$253Mobtainable near-term
Serviceable (SAM)$1.65Breachable market
Primary motionPartner-led + digitalgo-to-market
Time to scale3 Qto full motion
Ideal customer profile (who to sell to)
§GTM 1 · p.190 →Champion88 fit
Benchtop Cell Sorters
Best fit — highest urgency & budget in Product Type.
Economic buyer79 fit
Floor-standing Cell Sorters
Strong fit — clear ROI and a fast path to value.
End user65 fit
Portable Cell Sorters
Emerging fit — growing demand, longer sales cycle.
Market-entry sequence (beachhead → scale)
Fig. GTM 1 · p.192 →Beachhead · 2025–2026
Win Product Type in North America
Concentrated ICP, fastest proof and references.
Expand · 2026–2028
Add Technology & next regions
Repeat the motion in adjacent, look-alike segments.
Scale · 2028–2033
Full-market coverage + Application
Multi-channel, platform & ecosystem plays.
Channel mix (routes to market)
§GTM 3 · p.195 →Direct sales45%
Partner / channel24%
Digital / self-serve22%
Marketplaces9%
Positioning & messaging
§GTM 2 · p.194 →For Product Type leaders who need defensible market intelligence, VM Intelligence is the fastest, source-cited way to size, segment and win Tumor Cell Sorter Market — unlike generic, static research.
Live & source-cited
Every figure triangulated from 600K+ sources and traceable.
Ready in minutes
A full, tailored report compiled on demand — not weeks.
Scope you control
Pick the chapters, regions and companies that matter.
GTM funnel & unit economics (conversion · CAC / LTV)
Fig. GTM 2 · p.198 →Awareness100%
Marketing qualified44%
Sales qualified25%
Evaluation14%
Closed-won6%
$13.0KCAC
$45KLTV
3.4:1LTV : CAC
< 3 moCAC payback
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Investment thesis
Tumor Cell Sorter Market is a resilient opportunity — $5.43B by 2033, compounding at 3.7%.
TAM · 2025$4.08Btoday
TAM · 2033$5.43Bforecast
CAGR3.7%2027–2033
Cumulative$42.5Brevenue opportunity
Market opportunity (TAM · SAM · SOM)
Fig. 3 · p.14 →TAM$5.43BTotal addressable market
SAM$2.04BServiceable available market
SOM$349MServiceable obtainable market
Growth trajectory (USD Million)
Fig. 4 · p.16 →Why invest now
§2.1 · p.10 →3.7% CAGR
Demand compounds through 2033, outpacing GDP across Product Type.
Global tailwinds
North America leads today; fastest gains coming from emerging regions.
Structural shift
Adoption in Product Type moving from early to mainstream — durable secular demand.
Consolidation upside
13+ players, no runaway leader — room to build scale and roll up share.
Investment highlights
§2.2 · p.12 →$5.43BLarge & growingTAM by 2033 at 3.7% CAGR
$2.04BServiceable nowreachable with today’s model
$349MBeachhead winobtainable near-term share
13+Fragmented fieldplayers — consolidation runway
Return scenarios (2033 market value)
Fig. 6 · p.22 →$4.24BBear2.4% CAGR
$5.43BBase3.7% CAGR
$6.95BBull4.8% CAGR
Key risks & mitigants
§9.1 · p.180 →- Input-cost volatilityLong-term supply contracts & hedging
- Regulatory / policy shiftsDiversified exposure across 5 regions
- Technology disruptionR&D pipeline & Technology optionality
- Customer concentrationBroaden installed base beyond top accounts
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Board pack · executive summary
Tumor Cell Sorter Market — a $5.37B market by 2033. Plan: grow share from 11.7% to 18.0%.
Market size · 2033$5.37Btotal addressable
Market CAGR9.2%2027–2033
Target share18.0%from 11.7% today
Revenue ambition$966Mby 2033
Strategic scorecard (current vs 2033 target)
Table 1 · p.6 →| Objective | Current | Target · 2033 | Status |
|---|---|---|---|
| Market share | 11.7% | 18.0% | On track |
| Revenue | $608M | $966M | On track |
| Geographic coverage | 2 of 5 regions | 5 of 5 regions | On track |
| Segment coverage | 3 of 5 axes | 5 of 5 axes | Behind |
| Gross margin | 32.5% | 41.5% | At risk |
| Customer retention | 84.0% | 93.4% | On track |
Where to play (strategic priorities)
§1.2 · p.8 →1
Lead segment
Win in Product Type
Largest revenue pool and fastest secular demand — concentrate to build share here first.
2
Geographic
Expand across North America & beyond
Deepen the leading region, then scale into the fastest-growing emerging markets.
3
Adjacency
Build Technology capability
A defensible second engine — invest in Technology to widen the moat and cross-sell.
Strategic roadmap (2025–2033)
Fig. 1 · p.10 →Phase 1 · Foundation
2025–2027
- Secure core Product Type share
- Fix unit economics
- Stand up data & ops
Phase 2 · Scale
2028–2030
- Enter new regions
- Launch Technology
- Selective M&A
Phase 3 · Lead
2031–2033
- Category leadership
- Premium mix & margin
- Platform & ecosystem
Board decisions & asks
§1.4 · p.14 →- Approve $138M capacity & capability investment
- Greenlight bolt-on M&A in Technology
- Authorise North America expansion plan
- Fund R&D program for Product Type leadership
Risk watchlist (RAG)
§9 · p.180 →- Demand / macro slowdownAt risk
- Competitive share lossOn track
- Input-cost & supply riskBehind
- Regulatory / policy changeOn track
- Execution & talentBehind
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Sales deck · value proposition
Win the Tumor Cell Sorter Market conversation — a $2.24B market you can size, segment and defend in minutes.
Market size · 2033$2.24Btotal opportunity
Growth6.2%CAGR to 2033
Addressable buyers1,657+accounts in scope
Typical ROI4.8×in year one
Who buys (target personas)
§1.1 · p.4 →Product / BU leader
Head of Product Type
Goal Grow share in Product Type
Pain Blind spots on demand, pricing & competitors.
Regional GM
North America lead
Goal Prioritise the right markets
Pain No granular, country-level view of the market.
M&A / strategy
Strategy & Corp Dev
Goal Find where to invest or acquire
Pain Slow, inconsistent third-party research.
From pain to solution
§1.2 · p.6 →Decisions made on stale, generic dataLive, source-cited figures, continuously updated
Weeks waiting on a research vendorA full report compiled in minutes
No view of competitors or whitespaceCompany profiles, ACE matrix & benchmarking
Hard to defend the numbers internallyEvery figure traceable to its original source
The business case (ROI)
Fig. 2 · p.9 →4.8×return on cost, year one
< 3 mopayback period
$65K+research cost avoided
10×faster than a custom study
Time to insight
Cost to run
Risk of a wrong call
Why buyers trust it (proof points)
§1.3 · p.12 →600K+source studies indexed
100%analyst-reviewed
13+players profiled in this market
Coverage includes
BD BiosciencesBeckman Coulter Life SciencesSony BiotechnologyMiltenyi BiotecBio-Rad LaboratoriesSysmex CorporationThermo Fisher ScientificAgilent Technologies+5 more
Objection handling
§1.4 · p.14 →“We already have market data.”
This triangulates 600K+ sources into one current, defensible view — not another silo.
“How do we know it’s accurate?”
Analyst-reviewed, and every figure is source-cited and traceable to its origin.
“It’s not in the budget.”
A fraction of a single analyst-day — and it pays back on the first decision it informs.
“We need it tailored to us.”
Choose the chapters, regions and companies before you build — you only pay for scope.
What you get (packages)
§1.5 · p.16 →Report
- Full multi-chapter report
- Market size, share & forecast
- Segment & regional breakdowns
- PDF + editable Excel + PPT
Most popular
Report + Add-ons
- Everything in Report
- Interactive Visualizer
- Competitive benchmarking
- Investor / board / sales decks
Enterprise
- Multiple reports & markets
- Team seats & sharing
- Analyst support & custom scope
- API / data-feed options
Almost there
Access your Tumor Cell Sorter Market report
Sign in to unlock the full report - it’s compiled live and ready in minutes.
or continue with your email
Your report is ready to access
Tumor Cell Sorter Market Report is ready
Verify your email to unlock it. We sent a 6-digit code to your inbox.
That code is invalid or expired. Please try again.
Trusted by strategy, finance & consulting teams
Related Reports
Healthcare and Pharmaceuticals · scroll →Tumor Cell Isolation Kits Market
Market size, share, segmentation and regional forecast.
$3.3B market · 2025 base year
View reportTumor Blood Testing Market
Market size, share, segmentation and regional forecast.
$1.8B market · 2025 base year
View reportTumor Biomarker Test Market
Market size, share, segmentation and regional forecast.
$4.8B market · 2025 base year
View reportTumor Ablation Therapy Market
Market size, share, segmentation and regional forecast.
$1.9B market · 2025 base year
View reportTumor Ablation Therapy Device Market
Market size, share, segmentation and regional forecast.
$2.2B market · 2025 base year
View reportTumor Ablation Needle Market
Market size, share, segmentation and regional forecast.
$3.4B market · 2025 base year
View reportTumor Ablation Equipment Market
Market size, share, segmentation and regional forecast.
$3.3B market · 2025 base year
View reportTumor Ablation Equipment and Accessories Market
Market size, share, segmentation and regional forecast.
$4.2B market · 2025 base year
View reportTumor Ablation and Interventional Radiology Market
Market size, share, segmentation and regional forecast.
$5.9B market · 2025 base year
View reportTummy Tuck Market
Market size, share, segmentation and regional forecast.
$1.9B market · 2025 base year
View reportTumescent Liposuction Surgical Machine Market
Market size, share, segmentation and regional forecast.
$803M market · 2025 base year
View reportTumescent Liposuction Market
Market size, share, segmentation and regional forecast.
$2.3B market · 2025 base year
View reportThe showdown
Custom-built vs. off-the-shelf
Scroll to watch them go head-to-head
WinnerVMR Custom Report
- Tailored to your exact scope
- Delivered in minutes
- Live, always-current data
- Fully editable data (XLSX)
- You choose the companies
- Source-cited & traceable
Off-the-shelf PDF
- Generic, one-size template
- Waits 2–5 days
- A fixed snapshot in time
- Locked, flat PDF
- Preset company list
- Opaque sourcing
Customer Testimonials
Proof from industry leaders who rely on us
These stories come from the executives who depend on VMR’s intelligence for market entry, expansion, assessment, and planning. Their outcomes and experiences reflect our commitment to clarity.
600,000+source studies indexed
100%analyst-reviewed
Every figuresource-cited & traceable
In their words
Watch clients tell their story
How VMR helped University of Limerick with Anesthesia Monitoring Devices
How VMR helps brands expand into Africa & emerging markets
Unlock your GTM strategy: an Elsewedy Electric success story
Beyond sales data: layering NielsenIQ data to support strategy
How VMR became the trusted partner for United Alloy
Questions, answered
How is the research actually conducted?
Every report is compiled from VMR’s continuously-updated intelligence across 600,000+ source studies - primary interviews, company filings, trade data, and government & industry databases. Figures are triangulated across multiple credible sources, then reviewed by a research analyst before your report is delivered.
What exactly do I get inside the report?
A full multi-chapter study: market definition & methodology, executive summary, market outlook (drivers, restraints, trends, Porter’s Five Forces), segment deep-dives, regional & country breakdowns, competitive landscape, and a full profile for every company you select - with interactive charts and data tables throughout.
How accurate are the numbers, and can I trust them?
Market sizing is reconciled across leading sources (Gartner, BCG, MarketsandMarkets, government bodies and more), with outliers removed and a confidence-graded median used for the base year. Every figure is source-cited and traceable to its origin, and an analyst validates the model before delivery.
Can I customise the chapters, regions and companies?
Yes. Choose exactly the chapters, regions and countries, and the companies you want benchmarked before you build - then adjust your selection and recompile anytime from your account. You only pay for the scope you need.
What formats do I receive, and is the data editable?
Every report is readable online in full. Downloadable formats are available as optional $99 add-ons: a formatted PDF and a fully editable XLSX containing all underlying data tables - so you can re-chart, re-model, or drop any figure straight into your own deck.